Iron Chelation as Therapy for HIV and Mycobacterium tuberculosis Co-Infection Under Conditions of Iron Overload
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Iron chelators, as treatment for conditions of iron overload, have implications for AIDS and tuberculosis (TB) since excess iron in the system assists HIV and Mycobacterium tuberculosis (M.tb) multiplication. Excess iron, especially due to dietary habits, is almost as common in sub-Saharan Africa as infections by the two organisms. That HIV and M.tb influence each other's replication during co-infection is well established, but in vitro evaluations of concurrent infection of the two under conditions of iron overload and determining whether chelators reverse the effect, are limited. This review provides brief commentary on the possibility of iron chelators presently in clinical use influencing simultaneous HIV-M.tb infections during iron loading and the feasibility of evaluating this in vitro.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These chelators can alter the development of inflammatory diseases, have antiviral properties and can also be used in the treatment of malignancies (Meyer, 2006; Lehmann et al., 2015).”
From Iron at the Centre of Candida albicans Interactions (2018) · cites this paper as Meyer, 2006
In the citing paper
“Iron overload in the host can be due to hereditary or dietary factors and the main therapy for this is through the administration of small molecule chelators (Meyer, 2006).”
From Iron at the Centre of Candida albicans Interactions (2018) · cites this paper as Meyer, 2006
Citations
Cites
Collins, L., & Franzblau, S. G. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1004 · Cited by 1,599
Progress in understanding the pathogenesis of the anemia of chronic disease [see comments]
Means, R. J., & Krantz, S. (1992) · Blood · doi:10.1182/blood.v80.7.1639.1639 · Cited by 681 · cited 1×
“Iron plays a role in the outcome of many infections and overload of the metal can promote the frequency and severity of microorganism infections [12] in addition to altering immune- and other host cell defense responses [13-14].”
BackgroundEffect of Mycobacterium tuberculosis on HIV replication. Role of immune activation
Goletti, D., Weissman, D., Jackson, R. W., Graham, N. M., Vlahov, D., Klein, R. S., Munsiff, S. S., Ortona, L., Cauda, R., & Fauci, A. S. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.3.1271 · Cited by 495 · cited 2×
“Conversely, TB is accelerated by co-infection with HIV [1-5] and replication of both of these microorganisms is augmented by iron loading [6-9].”
BackgroundIron, mycobacteria and tuberculosis
Ratledge, C. (2004) · Tuberculosis · doi:10.1016/j.tube.2003.08.012 · Cited by 344
Gobin, J., & Horwitz, M. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1527 · Cited by 208
Gobin, J., Moore, C. H., Reeve, J. R., Wong, D. K., Gibson, B. W., & Horwitz, M. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.5189 · Cited by 180
Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients
Toossi, Z., Mayanja-Kizza, H., Hirsch, C. S., Edmonds, K. L., Spahlinger, T., Hom, D. L., Aung, H., Mugyenyi, P., Ellner, J. J., & Whalen, C. W. (2001) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2001.01401.x · Cited by 167 · cited 2×
“tb infection have been reported in sub-Saharan Africa [4] and 11% of all AIDSrelated deaths are due to tuberculosis [11].”
BackgroundMycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome
Collins, F. M. (1989) · Clinical Microbiology Reviews · doi:10.1128/cmr.2.4.360 · Cited by 157 · cited 1×
“Conversely, TB is accelerated by co-infection with HIV [1-5] and replication of both of these microorganisms is augmented by iron loading [6-9].”
BackgroundIron and Mycobacterium tuberculosis infection
Lounis, N., Truffot-Pernot, C., Grosset, J., Gordeuk, V. R., & Boelaert, J. R. (2001) · Journal of Clinical Virology · doi:10.1016/s1386-6532(00)00136-0 · Cited by 142 · cited 2×
“Excess iron enhances viral replication [7] and mycobacterial multiplication [6] and it does not seem to matter whether patients contract HIV or M.”
BackgroundIron and infection: competition between host and microbes for a precious element
MARX, J. (2002) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2002.0001 · Cited by 129 · cited 1×
“Iron plays a role in the outcome of many infections and overload of the metal can promote the frequency and severity of microorganism infections [12] in addition to altering immune- and other host cell defense responses [13-14].”
BackgroundIron status and the outcome of HIV infection: an overview
Gordeuk, V. R., Delanghe, J. R., Langlois, M. R., & Boelaert, J. R. (2001) · Journal of Clinical Virology · doi:10.1016/s1386-6532(00)00134-7 · Cited by 124 · cited 3×
“Excess iron enhances viral replication [7] and mycobacterial multiplication [6] and it does not seem to matter whether patients contract HIV or M.”
BackgroundIron Chelator Research: Past, Present, and Future
Tam, T., Leung-Toung, R., Li, W., Wang, Y., Karimian, K., & Spino, M. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033457593 · Cited by 116 · cited 6×
“Because of structural differences between DFO (a hexadentate ligand, [26, 16]) and L1 (a bidentate ligand, [26, 16]), the iron inactivating capacity of the latter chelator is concentration dependant [24].”
BackgroundInfluentialHershko, C. (1994) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(05)80133-7 · Cited by 105 · cited 1×
“This ability to decrease proliferation is being explored for treatment of malignant disease and as an indirect influence on viral replication [22].”
BackgroundGeorgiou, N. A., van der Bruggen, T., Oudshoorn, M., Nottet, H. S. L. M., Marx, J. J. M., & van Asbeck, B. S. (2000) · The Journal of Infectious Diseases · doi:10.1086/315223 · Cited by 105 · cited 3×
“Excess iron assists replication of HIV while withholding iron via chelation addition reversed the process [7-8, 23, 2829], suggesting that using chelators in combination with existing antivirals could improve the treatment of HIV-disease [24].”
BackgroundGordeuk, V. R. (2002) · Seminars in Hematology · doi:10.1053/shem.2002.35636 · Cited by 93 · cited 1×
“African iron overload is a result of increased absorption of iron in individuals from sub-Saharan Africa because of dietary habits [18, 19] or hereditary mutations [19-21] in African Americans, which are distinct from the HLA-linked mutation in Caucasians with genetic hemochromatosis [19-21].”
BackgroundIron withholding: A defense against viral infections
Weinberg, E. D. (1996) · BioMetals · doi:10.1007/bf00140609 · Cited by 88 · cited 1×
“Conversely, TB is accelerated by co-infection with HIV [1-5] and replication of both of these microorganisms is augmented by iron loading [6-9].”
BackgroundBleomycin pulmonary toxicity: current status and future directions.
Comis, R. L. (1992) · PubMed · Cited by 79
Genotypic and phenotypic heterogeneity of African Americans with primary iron overload
Barton, J. C., Acton, R. T., Rivers, C. A., Bertoli, L. F., Gelbart, T., West, C., & Beutler, E. (2003) · Blood Cells Molecules and Diseases · doi:10.1016/s1079-9796(03)00166-9 · Cited by 67 · cited 1×
“African iron overload is a result of increased absorption of iron in individuals from sub-Saharan Africa because of dietary habits [18, 19] or hereditary mutations [19-21] in African Americans, which are distinct from the HLA-linked mutation in Caucasians with genetic hemochromatosis [19-21].”
BackgroundThe Iron Chelator L1 Potentiates Oxidative DNA Damage in Iron-Loaded Liver Cells
Cragg, L., Hebbel, R. P., Miller, W., Solovey, A., Selby, S., & Enright, H. (1998) · Blood · doi:10.1182/blood.v92.2.632 · Cited by 66
Anti-HIV effect of iron chelators: different mechanisms involved
van Asbeck, B. S., Georgiou, N., van der Bruggen, T., Oudshoorn, M., Nottet, H. S. L. M., & Marx, J. J. M. (2001) · Journal of Clinical Virology · doi:10.1016/s1386-6532(00)00122-0 · Cited by 65 · cited 5×
“Because of structural differences between DFO (a hexadentate ligand, [26, 16]) and L1 (a bidentate ligand, [26, 16]), the iron inactivating capacity of the latter chelator is concentration dependant [24].”
BackgroundInfluentialDesign of Orally Active Iron Chelators
Hider, R. C., Choudhury, R., Rai, B. L., Dehkordi, L. S., & Singh, S. (1996) · Acta Haematologica · doi:10.1159/000203851 · Cited by 61 · cited 1×
“Because of structural differences between DFO (a hexadentate ligand, [26, 16]) and L1 (a bidentate ligand, [26, 16]), the iron inactivating capacity of the latter chelator is concentration dependant [24].”
BackgroundIdentification and Validation of Novel Drug Targets in Tuberculosis
Duncan, K. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383223 · Cited by 60
Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis
Pedral-Sampaio, D., Alves, C. R., Netto, E. M., Brites, C. R., Oliveira, A. M., & Badaró, R. J. D. S. (2004) · The Brazilian Journal of Infectious Diseases · doi:10.1590/s1413-86702004000300004 · Cited by 60 · cited 1×
“tb infection have been reported in sub-Saharan Africa [4] and 11% of all AIDSrelated deaths are due to tuberculosis [11].”
BackgroundDifferential regulation and expression of stress proteins and ferritin in human monocytes
Bornman, L., Baladi, S., Richard, M.-J., Tyrrell, R. M., & Polla, B. S. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199901)178:1<1::aid-jcp1>3.0.co;2-q · Cited by 49 · cited 1×
“Non-radioactive iron can also be used to load cells in vitro [28-30].”
BackgroundAn Overview of Iron Metabolism: Molecular and Cellular Criteria for the Selection of Iron Chelators
Crichton, R., & Ward, R. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033457566 · Cited by 46 · cited 5×
“tb infection [15].”
BackgroundInfluentialTuberculosis and iron overload in Africa: a review.
Moyo, V. M., Gangaidzo, I. T., Gordeuk, V. R., Kiire, C. F., & MacPhail, A. P. (1997) · PubMed · Cited by 44
Georgiou, N. A., Van Der Bruggen, T., Oudshoorn, M., Hider, R. C., Marx, J. J. M., & Van Asbeck, B. S. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.0320s1091.x · Cited by 38 · cited 2×
“Excess iron assists replication of HIV while withholding iron via chelation addition reversed the process [7-8, 23, 2829], suggesting that using chelators in combination with existing antivirals could improve the treatment of HIV-disease [24].”
BackgroundMeylan, P. R., Munis, J. R., Richman, D. D., & Kornbluth, R. S. (1992) · The Journal of Infectious Diseases · doi:10.1093/infdis/165.1.80 · Cited by 36 · cited 2×
“tb and HIV on each other, may not always agree with the clinical evidence [31-32].”
BackgroundIron overload and tuberculosis: a case for iron chelation therapy.
Cronjé, L., & Bornman, L. (2005) · PubMed · Cited by 36
Effect on ribonucleotide reductase of novel lipophilic iron chelators: the desferri-exochelins
Hodges, Y. K., Antholine, W. E., & Horwitz, L. D. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.101 · Cited by 31 · cited 1×
“DFO has also been successfully tested as inhibitor of mycobacterium infections [25] even though desferri-exochelins (siderophores secreted by M.”
BackgroundStructural Bioinformatic Approaches to the Discovery of New Antimycobacterial Drugs
Kantardjieff, K. A., & Rupp, B. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383205 · Cited by 26
Characterization of Exochelins of the Mycobacterium bovis Type Strain and BCG Substrains
Gobin, J., Wong, D. K., Gibson, B. W., & Horwitz, M. A. (1999) · Infection and Immunity · doi:10.1128/iai.67.4.2035-2039.1999 · Cited by 25
Biswas, P., Ferrarini, M., Mantelli, B., Fortis, C., Poli, G., Lazzarin, A., & Manfredi, A. A. (2003) · European Journal of Immunology · doi:10.1002/immu.200390028 · Cited by 18
Traoré, H. N., & Meyer, D. (2001) · Methods in Cell Science · doi:10.1023/a:1016313221027 · Cited by 11 · cited 2×
“Confirmation of successful in vitro loading of uninfected cells with iron can be done with inductively coupled plasma-atomic emission spectroscopy (ICP-AES) and has been demonstrated for 3 different cell types using either FeSO4 or Fe-EDTA as iron source [28].”
BackgroundMethodSelf-citationDouvas, G. S., May, M. H., Kolnagou, A., & Kontoghiorghes, G. J. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1299855 · Cited by 10
Ward, G. C. (1987) · Journal of Burn Care & Rehabilitation · doi:10.1097/00004630-198708060-00007 · Cited by 6
The antituberculous effect of bleomycin
Ertem, E., Yüce, K., KARAKARTAL, G. Ü., ÜNAL, O., & Yüce, G. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/26.6.862 · Cited by 3
Cited by
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“[136; 149; 1335; 1352-1371]), and its chelation in a form not available to bacteria offers a route to at least a bacteriostatic kind of antibiotic or to novel therapies based on the lowering of iron available to microbes by using hepcidin [1372].”
BackgroundA major role for ferroptosis in Mycobacterium tuberculosis –induced cell death and tissue necrosis
Amaral, E. P., Costa, D. L., Namasivayam, S., Riteau, N., Kamenyeva, O., Mittereder, L., Mayer-Barber, K. D., Andrade, B. B., & Sher, A. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181776 · Cited by 464
“In contrast, iron chelation and mutations in host or bacterial genes affecting iron availability typically restrict pathogen growth (Schaible et al., 2002; Meyer, 2006; Owens et al., 2013; Boradia et al., 2014; Dragset et al., 2015).”
BackgroundKell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“…of superoxide, peroxide and the hydroxyl radical involving poorly liganded iron can exert a positive feedback leading to the death of cells 2009; Meyer 2006; Northrop-Clewes 2008; Rawat et al. 2008; Savarino et al. 1999; Schreck et al. 1992; Szajerka and Jablecki 2007; Traoré and Meyer 2004,…”
BackgroundIron at the Centre of Candida albicans Interactions
Fourie, R., Kuloyo, O. O., Mochochoko, B. M., Albertyn, J., & Pohl, C. H. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00185 · Cited by 118
“These chelators can alter the development of inflammatory diseases, have antiviral properties and can also be used in the treatment of malignancies (Meyer, 2006; Lehmann et al., 2015).”
BackgroundBasaraba, R. J. (2008) · Tuberculosis · doi:10.1016/s1472-9792(08)70035-0 · Cited by 136
“Iron chelation therapy has been suggested as an alternative therapy in tuberculosis patients as well as those co-infected with HIV.(128,134,135) Therefore, the targeting of lesion-associated iron with iron chelator represents an alternative strategy to treat tuberculosis either alone or in combination with conventiona…”
Background
Metadata
- Authors
- Meyer, D.
- Affiliations
- University of Johannesburg (ZA)
- Corresponding author
- Meyer, Debra
- ORCID
- Meyer, Debra
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-06-01
- Volume
- 12
- Issue
- 16
- Pages
- 1943-1947
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2044191483
- Cited by
- 34
- References
- 37
- Citations by year
- 2025: 1 · 2024: 2 · 2022: 1 · 2021: 1 · 2020: 4 · 2019: 2 · 2018: 5 · 2017: 1 · 2015: 1 · 2014: 2 · 2013: 2 · 2012: 1
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- iron chelation, iron overload, HIV, Mycobacterium tuberculosis, tuberculosis-HIV coinfection, iron chelators, sub-Saharan Africa, dietary iron
- MeSH terms
- HIV, Humans, Iron, Iron Chelating Agents, Macrophages, Mycobacterium tuberculosis, Tuberculosis, HIV Infections, Iron Overload
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.